Patients with NAFLD have reduced GLP-1 levels, and when used as a therapeutic approach, GLP-1 analogs have an indirect impact on hepatic metabolism, reducing hepatic steatosis, inflammation and, to a lesser extent, fibrosis [4,5]. The gene discussed is GLP1R; the disease is fatty liver disease.